---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-001941"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-05-23T23:59:59+00:00"
generated_at: "2026-05-20T15:46:28.200094+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Silexion Therapeutics receives Nasdaq delisting notice; plans appeal

## Summary
- Received delisting notice on May 22, 2025 for MVLS <$50M and MVPHS <$15M non-compliance.
- Failed to regain compliance within 180-day period ending May 19, 2025.
- Intends to appeal by May 29, 2025; trading suspension effective June 2, 2025 if appeal fails.
- Plans to request transfer to Nasdaq Capital Market; requires at least $2.5M shareholders' equity.

## SEC filing metadata
- accession: 0001178913-25-001941
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-05-23T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325001941/0001178913-25-001941-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325001941/zk2533256.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-001941
- JSON: https://secwatch.observer/filing/0001178913-25-001941.json
- Plain text: https://secwatch.observer/filing/0001178913-25-001941.txt

## Key facts
- Listing & Compliance Notices
  Silexion Therapeutics Corp received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(A)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: market value
  - Rules: 5450(b)(2)(A)
  source text: ”) , which would remove the Company’s ordinary shares and warrants from listing and registration on Nasdaq. The listing deficiencies, for which we had received two letters from the Nasdaq Listing Qualifications Department on November 19, 2024, relate to our non-compliance with Nasdaq Listing Rules 5450(b)(2)(A) and 5450(b)(2)(C). Those rules require a company such as ours whose securities are listed on the Nasdaq Global Market under the “Market Value Standard” to maintain a minimum Market Value of Listed Securities (an “ MVLS ”) of $50,000,000 and a minimum Market Value of Publicly Held Shar
  evidence_url: https://www.sec.gov/Archives/edgar/data/2022416/000117891325001941/0001178913-25-001941-index.htm
- Listing & Compliance Notices
  Silexion Therapeutics Corp received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(C)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: market value
  - Rules: 5450(b)(2)(C)
  source text: ”) , which would remove the Company’s ordinary shares and warrants from listing and registration on Nasdaq. The listing deficiencies, for which we had received two letters from the Nasdaq Listing Qualifications Department on November 19, 2024, relate to our non-compliance with Nasdaq Listing Rules 5450(b)(2)(A) and 5450(b)(2)(C). Those rules require a company such as ours whose securities are listed on the Nasdaq Global Market under the “Market Value Standard” to maintain a minimum Market Value of Listed Securities (an “ MVLS ”) of $50,000,000 and a minimum Market Value of Publicly Held Shar
  evidence_url: https://www.sec.gov/Archives/edgar/data/2022416/000117891325001941/0001178913-25-001941-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.